These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38727208)

  • 1. Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.
    Ward GA; Zhang Z; Jueliger S; Potapov IS; Davis MP; Boxall AR; Taylor J; Keer H; Biondo A; Lyons JF; Sims M; Smyth T
    Cancer Res Commun; 2024 Jun; 4(6):1441-1453. PubMed ID: 38727208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.
    Ferrari N; Ward G; Gewinner C; Davis MP; Jueliger S; Saini H; Munck J; Smyth T; Ferraldeschi R; Keer H; Lyons J; Sims MJ
    Blood Adv; 2021 Oct; 5(20):4003-4016. PubMed ID: 34474469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
    Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
    Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.
    Scotto L; Kinahan C; Douglass E; Deng C; Safari M; Casadei B; Marchi E; Lue JK; Montanari F; Falchi L; Qiao C; Renu N; Bates SE; Califano A; O'Connor OA
    Mol Cancer Ther; 2021 Aug; 20(8):1422-1430. PubMed ID: 34108263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
    Steinhart L; Belz K; Fulda S
    Cell Death Dis; 2013 Sep; 4(9):e802. PubMed ID: 24030154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.
    Jain S; Washington A; Leaf RK; Bhargava P; Clark RA; Kupper TS; Stroopinsky D; Pyzer A; Cole L; Nahas M; Apel A; Rosenblatt J; Arnason J; Kufe D; Avigan D
    Mol Cancer Ther; 2017 Oct; 16(10):2304-2314. PubMed ID: 28729399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.
    Wang Y; Tong C; Dai H; Wu Z; Han X; Guo Y; Chen D; Wei J; Ti D; Liu Z; Mei Q; Li X; Dong L; Nie J; Zhang Y; Han W
    Nat Commun; 2021 Jan; 12(1):409. PubMed ID: 33462245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination effect of epigenetic regulation and ionizing radiation in colorectal cancer cells.
    Kim JG; Bae JH; Kim JA; Heo K; Yang K; Yi JM
    PLoS One; 2014; 9(8):e105405. PubMed ID: 25136811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA Methylation as a Therapeutic Target for Bladder Cancer.
    Nunes SP; Henrique R; Jerónimo C; Paramio JM
    Cells; 2020 Aug; 9(8):. PubMed ID: 32784599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells.
    Frazzi R; Cusenza VY; Pistoni M; Canovi L; Cascione L; Bertoni F; Merli F
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma.
    Lai TJ; Sun L; Li K; Prins TJ; Treger J; Li T; Sun MZ; Nathanson DA; Liau LM; Lai A; Prins RM; Everson RG
    Cancer Res Commun; 2024 Jul; 4(7):1834-1849. PubMed ID: 38856710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel smac mimetic ASTX660 (Tolinapant) and TNF-α synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition.
    Wang L; Hu C; Zhao Y; Hu X
    Biochem Biophys Res Commun; 2022 Apr; 602():8-14. PubMed ID: 35247703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Silencing of
    Lee P; Yim R; Miu KK; Fung SH; Liao JJ; Wang Z; Li J; Yung Y; Chu HT; Yip PK; Lee E; Tse E; Kwong YL; Gill H
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
    Tang Z; Liu L; Borlak J
    Clin Epigenetics; 2023 May; 15(1):89. PubMed ID: 37208732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-adenosylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and metastasis.
    Mahmood N; Arakelian A; Cheishvili D; Szyf M; Rabbani SA
    J Cell Mol Med; 2020 Sep; 24(18):10322-10337. PubMed ID: 32720467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer : a study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres.
    Hoskin P; Lee M; Dunkley D; Danh M; Wickens R; Saunders G; Northey J; Crabb S; McFarlane V; Sadozye A; Cooper R; Mathew T; Haslett K; Reeves K; Reed R; Bigos K; Williams KJ; Rowling E; Choudhury A; Dancer S; Smith D; Griffiths G
    BMC Cancer; 2024 Jun; 24(1):702. PubMed ID: 38849715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
    Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.